Tff Common Stock vs Net Receivables Analysis

TFFP Stock

USD 2.16 0.15 7.46%

Tff Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tff Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tff Pharmaceuticals is a good investment. Please check the relationship between Tff Pharmaceuticals Common Stock and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tff Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Tff Stock, please use our How to Invest in Tff Pharmaceuticals guide.

Common Stock vs Net Receivables

Common Stock vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tff Pharmaceuticals Common Stock account and Net Receivables. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Tff Pharmaceuticals' Common Stock and Net Receivables is -0.27. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Tff Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Tff Pharmaceuticals' Common Stock and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Tff Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Common Stock i.e., Tff Pharmaceuticals' Common Stock and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock

Net Receivables

Most indicators from Tff Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tff Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tff Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Tff Stock, please use our How to Invest in Tff Pharmaceuticals guide.As of 05/20/2024, Selling General Administrative is likely to drop to about 6.8 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 4.8 M

Tff Pharmaceuticals fundamental ratios Correlations

	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock Shares Outstanding	Non Current Liabilities Total	Net Invested Capital	Net Working Capital	Other Current Liab	Net Debt	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab	Capital Stock	Common Stock	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings Total Equity	Property Plant And Equipment Gross
Total Current Liabilities		0.56	0.87	-0.9	0.84	0.88	-0.78	0.22	0.51	0.47	0.23	-0.18	-0.71	0.18	0.83	0.83	0.81	0.86	-0.71	-0.8	0.28	-0.71	0.65	0.69	-0.81	0.65
Total Stockholder Equity	0.56		0.74	-0.45	0.88	0.74	-0.84	0.79	0.98	0.99	-0.64	-0.9	0.03	0.9	0.79	0.74	0.86	0.66	0.03	-0.82	0.83	0.03	0.36	0.28	-0.47	0.36
Net Tangible Assets	0.87	0.74		-0.91	0.88	0.87	-0.97	0.4	0.77	0.65	-0.11	-0.42	-0.58	0.42	0.97	0.94	0.96	0.95	-0.58	-0.98	0.57	-0.58	0.73	0.74	-0.81	0.73
Retained Earnings	-0.9	-0.45	-0.91		-0.75	-0.79	0.8	-0.02	-0.47	-0.33	-0.19	0.05	0.72	-0.05	-0.87	-0.89	-0.82	-0.95	0.72	0.83	-0.37	0.72	-0.88	-0.92	0.92	-0.88
Accounts Payable	0.84	0.88	0.88	-0.75		0.87	-0.87	0.52	0.86	0.82	-0.27	-0.64	-0.29	0.64	0.91	0.91	0.95	0.87	-0.29	-0.88	0.68	-0.29	0.58	0.56	-0.73	0.58
Total Liab	0.88	0.74	0.87	-0.79	0.87		-0.88	0.48	0.69	0.68	-0.08	-0.42	-0.43	0.42	0.91	0.89	0.83	0.86	-0.43	-0.88	0.47	-0.43	0.56	0.61	-0.7	0.56
Common Stock Shares Outstanding	-0.78	-0.84	-0.97	0.8	-0.87	-0.88		-0.57	-0.86	-0.78	0.3	0.58	0.42	-0.57	-0.97	-0.91	-0.95	-0.89	0.42	1.0	-0.68	0.42	-0.65	-0.64	0.71	-0.65
Non Current Liabilities Total	0.22	0.79	0.4	-0.02	0.52	0.48	-0.57		0.74	0.84	-0.67	-0.84	0.18	0.83	0.43	0.31	0.48	0.21	0.18	-0.54	0.53	0.18	-0.15	-0.17	0.11	-0.15
Net Invested Capital	0.51	0.98	0.77	-0.47	0.86	0.69	-0.86	0.74		0.96	-0.63	-0.9	0.01	0.9	0.81	0.76	0.88	0.68	0.01	-0.85	0.84	0.01	0.38	0.3	-0.49	0.38
Net Working Capital	0.47	0.99	0.65	-0.33	0.82	0.68	-0.78	0.84	0.96		-0.69	-0.94	0.12	0.94	0.71	0.65	0.79	0.56	0.12	-0.76	0.81	0.12	0.24	0.16	-0.36	0.24
Other Current Liab	0.23	-0.64	-0.11	-0.19	-0.27	-0.08	0.3	-0.67	-0.63	-0.69		0.78	-0.66	-0.79	-0.21	-0.16	-0.31	-0.07	-0.66	0.27	-0.81	-0.66	-0.02	0.11	-0.11	-0.02
Net Debt	-0.18	-0.9	-0.42	0.05	-0.64	-0.42	0.58	-0.84	-0.9	-0.94	0.78		-0.35	-1.0	-0.49	-0.43	-0.6	-0.31	-0.35	0.55	-0.75	-0.35	0.01	0.11	0.11	0.01
Other Assets	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.66	-0.35		0.36	-0.41	-0.39	-0.37	-0.49	1.0	0.45	0.26	1.0	-0.46	-0.54	0.55	-0.46
Cash And Short Term Investments	0.18	0.9	0.42	-0.05	0.64	0.42	-0.57	0.83	0.9	0.94	-0.79	-1.0	0.36		0.49	0.43	0.6	0.31	0.36	-0.55	0.76	0.36	-0.01	-0.11	-0.11	-0.01
Common Stock Total Equity	0.83	0.79	0.97	-0.87	0.91	0.91	-0.97	0.43	0.81	0.71	-0.21	-0.49	-0.41	0.49		0.99	0.96	0.97	-0.41	-0.97	0.65	-0.41	0.72	0.74	-0.8	0.72
Capital Surpluse	0.83	0.74	0.94	-0.89	0.91	0.89	-0.91	0.31	0.76	0.65	-0.16	-0.43	-0.39	0.43	0.99		0.94	0.99	-0.39	-0.92	0.64	-0.39	0.77	0.79	-0.85	0.77
Other Current Assets	0.81	0.86	0.96	-0.82	0.95	0.83	-0.95	0.48	0.88	0.79	-0.31	-0.6	-0.37	0.6	0.96	0.94		0.93	-0.37	-0.96	0.74	-0.37	0.71	0.67	-0.79	0.71
Other Stockholder Equity	0.86	0.66	0.95	-0.95	0.87	0.86	-0.89	0.21	0.68	0.56	-0.07	-0.31	-0.49	0.31	0.97	0.99	0.93		-0.49	-0.9	0.59	-0.49	0.84	0.87	-0.9	0.84
Deferred Long Term Liab	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.66	-0.35	1.0	0.36	-0.41	-0.39	-0.37	-0.49		0.45	0.26	1.0	-0.46	-0.54	0.55	-0.46
Capital Stock	-0.8	-0.82	-0.98	0.83	-0.88	-0.88	1.0	-0.54	-0.85	-0.76	0.27	0.55	0.45	-0.55	-0.97	-0.92	-0.96	-0.9	0.45		-0.66	0.45	-0.66	-0.66	0.73	-0.66
Common Stock	0.28	0.83	0.57	-0.37	0.68	0.47	-0.68	0.53	0.84	0.81	-0.81	-0.75	0.26	0.76	0.65	0.64	0.74	0.59	0.26	-0.66		0.26	0.55	0.43	-0.48	0.55
Other Liab	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.66	-0.35	1.0	0.36	-0.41	-0.39	-0.37	-0.49	1.0	0.45	0.26		-0.46	-0.54	0.55	-0.46
Property Plant And Equipment Net	0.65	0.36	0.73	-0.88	0.58	0.56	-0.65	-0.15	0.38	0.24	-0.02	0.01	-0.46	-0.01	0.72	0.77	0.71	0.84	-0.46	-0.66	0.55	-0.46		0.97	-0.91	1.0
Current Deferred Revenue	0.69	0.28	0.74	-0.92	0.56	0.61	-0.64	-0.17	0.3	0.16	0.11	0.11	-0.54	-0.11	0.74	0.79	0.67	0.87	-0.54	-0.66	0.43	-0.54	0.97		-0.88	0.97
Retained Earnings Total Equity	-0.81	-0.47	-0.81	0.92	-0.73	-0.7	0.71	0.11	-0.49	-0.36	-0.11	0.11	0.55	-0.11	-0.8	-0.85	-0.79	-0.9	0.55	0.73	-0.48	0.55	-0.91	-0.88		-0.91
Property Plant And Equipment Gross	0.65	0.36	0.73	-0.88	0.58	0.56	-0.65	-0.15	0.38	0.24	-0.02	0.01	-0.46	-0.01	0.72	0.77	0.71	0.84	-0.46	-0.66	0.55	-0.46	1.0	0.97	-0.91

Click cells to compare fundamentals

Tff Pharmaceuticals Account Relationship Matchups

Tff Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	410.6K	1.3M	2.0M	1.1M	2.4M	2.5M
Total Stockholder Equity	27.6M	37.3M	38.7M	22.9M	9.6M	9.1M
Net Tangible Assets	(3.2M)	27.6M	37.3M	38.7M	44.5M	46.8M
Retained Earnings	(15.7M)	(34.3M)	(65.3M)	(97.1M)	(118.3M)	(112.4M)
Accounts Payable	410.6K	1.3M	1.5M	919.6K	958.4K	759.2K
Total Liab	1.5M	1.3M	2.0M	1.2M	2.5M	1.3M
Total Assets	29.2M	38.7M	40.7M	24.1M	12.0M	11.4M
Cash	28.1M	35.3M	33.8M	16.6M	5.5M	5.2M
Common Stock Shares Outstanding	276.2K	817.0K	992.8K	1.2M	1.8M	1.7M
Non Current Liabilities Total	1.1M	1.3M	416.9K	110.1K	31.7K	30.2K
Net Invested Capital	27.6M	37.3M	38.7M	22.9M	9.6M	9.1M
Total Current Assets	29.2M	37.6M	38.8M	19.0M	7.6M	7.2M
Net Working Capital	28.8M	36.2M	36.9M	17.9M	5.2M	4.9M
Net Debt	(28.1M)	(35.3M)	(33.8M)	(16.4M)	(5.4M)	(5.6M)
Cash And Short Term Investments	28.1M	35.3M	33.8M	16.6M	5.5M	5.2M
Liabilities And Stockholders Equity	29.2M	38.7M	40.7M	24.1M	12.0M	20.7M
Other Current Assets	1.1M	2.3M	2.4M	2.2M	1.7M	1.8M
Other Stockholder Equity	43.3M	71.6M	104.1M	120.1M	128.0M	88.0M
Accumulated Other Comprehensive Income	(29.2M)	(51.5K)	(48.9K)	(139.3K)	(148.2K)	(155.6K)
Capital Stock	18.5K	22.5K	25.4K	36.2K	2.4K	2.3K
Common Stock	18.5K	22.5K	25.4K	36.2K	2.4K	2.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tff Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Tff Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Tff Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Tff Pharmaceuticals Stock:

How To Invest In Tff

Details

Is Tff Stock a good investment?

Details

What is Tff Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tff Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Tff Stock, please use our How to Invest in Tff Pharmaceuticals guide.

Note that the Tff Pharmaceuticals information on this page should be used as a complementary analysis to other Tff Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Tff Stock analysis

When running Tff Pharmaceuticals' price analysis, check to measure Tff Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tff Pharmaceuticals is operating at the current time. Most of Tff Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tff Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tff Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tff Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas

Is Tff Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tff Pharmaceuticals. If investors know Tff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tff Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.85)

Revenue Per Share

0.409

Quarterly Revenue Growth

(0.63)

Return On Assets

(0.76)

Return On Equity

(1.31)

The market value of Tff Pharmaceuticals is measured differently than its book value, which is the value of Tff that is recorded on the company's balance sheet. Investors also form their own opinion of Tff Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tff Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tff Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tff Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tff Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tff Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tff Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tff Common Stock vs Net Receivables Analysis

Common Stock vs Net Receivables

Common Stock vs Net Receivables Correlation Analysis

Correlation Coefficient

Common Stock

Net Receivables

Tff Pharmaceuticals fundamental ratios Correlations

Tff Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tff Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Tff Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Stock	+ 1.0	Common Stock Shares Outstanding
Deferred Long Term Liab	+ 1.0	Other Assets
Other Liab	+ 1.0	Other Assets
Other Liab	+ 1.0	Deferred Long Term Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Working Capital	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Capital Stock	- 0.98	Net Tangible Assets
Capital Stock	- 0.97	Common Stock Total Equity
Common Stock Total Equity	- 0.97	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.97	Net Tangible Assets
Capital Stock	- 0.96	Other Current Assets